Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.

TitleCost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Publication TypeJournal Article
Year of Publication2012
AuthorsChau D, Becker D, Coombes M, Ioannidis G, Adachi J, Goeree R
JournalJournal of medical economics
Volume15 Suppl 1
Pagination3-14
Date Published2012
Abstract

Denosumab is a novel biologic agent approved in Canada for treatment of post-menopausal osteoporosis (PMO) in women at high risk for fracture or who have failed or are intolerant to other osteoporosis therapies. This study estimated cost-effectiveness of denosumab vs usual care from the perspective of the Ontario public payer.

DOI10.1016/j.jviromet.2013.02.009
Alternate JournalJ Med Econ